What is the clinical evidence from this study?

Study design: Review. Population: Immune checkpoint inhibitor-associated myocarditis. Intervention: Immunosuppressive therapy (corticosteroids and second-line agents).

What does this research mean for the field?

Effective management of immune checkpoint inhibitor-associated myocarditis requires a structured, multidisciplinary approach involving early recognition, systematic risk stratification, prompt high-dose corticosteroids, and a structured escalation strategy for refractory cases. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

September 14, 2026Discover MedicineOpen Access

Current evidence on the diagnosis and management of immune checkpoint inhibitor associated myocarditis

View Full Paper

Ask AI

Bookmark

Key result

Prompt high-dose immunosuppression is critical for ICI myocarditis given its ~26% mortality.

Why the study?

Immune checkpoint inhibitor-associated myocarditis is a rare but life-threatening adverse event with limited evidence guiding diagnosis and immunosuppressive management.

Population

Patients with immune checkpoint inhibitor-associated myocarditis

Comparison

High-dose intravenous methylprednisolone first-line therapy versus second-line immunosuppressive agents

Design

Narrative review synthesizing observational data and guideline recommendations

Authors

YAYasar AhmedUniversity College Dublin HIHatim IbrahimSt. Vincent's University Hospital DSDiya M. SabuSt. Vincent's University Hospital

Discussion

Member takes

Implication

Supports prompt ICI-M recognition and corticosteroid use per IC-OS criteria; extends pathways but remains hypothesis-generating.

Key Points

Synthesize the latest clinical evidence on epidemiology, diagnosis, risk stratification, and immunosuppressive management for immune checkpoint inhibitor-associated myocarditis.
Conducted a narrative review analyzing recent epidemiological cohorts, diagnostic criteria from the 2021 IC-OS consensus and 2024 ACC Consensus Pathway, and immunosuppression management strategies.
Evaluated diagnostic performance combining high-sensitivity troponin with multimodal imaging after excluding acute coronary syndrome and infectious causes.
ICI-associated myocarditis incidence spans 1% in monotherapy to 2-4% in combination regimens, with pooled mortality reaching approximately 26% (historically 27% to 50%).
High-dose intravenous methylprednisolone represents the standard first-line treatment, but up to 50% of severe cases prove steroid-refractory and demand treatment escalation.
Current evidence supporting second-line agents—including abatacept, infliximab, mycophenolate mofetil, and tacrolimus—stems from observational cohorts and case series without randomized trial validation.

Structured PICO

Population

Patients receiving immune checkpoint inhibitors who develop immune checkpoint inhibitor-associated myocarditis (ICI-M).

Intervention

High-dose intravenous methylprednisolone as first-line therapy, and second-line immunosuppressive agents (mycophenolate mofetil, tacrolimus, abatacept, anti-thymocyte globulin, infliximab, tocilizumab, ruxolitinib) for steroid-refractory disease.

This narrative review synthesizes current observational evidence and guidelines for the multidisciplinary diagnosis, risk stratification, and immunosuppressive management of immune checkpoint inhibitor-associated myocarditis.

Limitations

The evidence base for immune checkpoint inhibitor-associated myocarditis remains largely observational.
Evidence for second-line immunosuppressive agents derives from case series and small cohorts rather than randomised trials.
Evidence for second-line agents derives from case series and small cohorts rather than randomised trials

Cite This Study

Ahmed et al. (2026) conducted a review in Immune checkpoint inhibitor-associated myocarditis. Immunosuppressive therapy (corticosteroids and second-line agents) was evaluated. Immune checkpoint inhibitor-associated myocarditis is a life-threatening complication with approximately 26% mortality, requiring early recognition and prompt high-dose immunosuppression.

synapsesocial.com/papers/6aa7afef79e9260bc85aacba https://doi.org/10.1007/s44337-026-00696-4

Topics

Myocarditis

View Full Paper

Ask AI

Bookmark

Current evidence on the diagnosis and management of immune checkpoint inhibitor associated myocarditis

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

Current evidence on the diagnosis and management of immune checkpoint inhibitor associated myocarditis

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider